GlassScriptPhysician profile
Janet E Debarbieris
NPI 1760116941
$3,285.60
in general payments reported to CMS, 2019-2025
21 companies · $1,892 in 2025
The $1,892 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $20.66 · 2023: $356 · 2024: $1,017 · 2025: $1,892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,264.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $648.85 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $342.97 | 2024 | Farxiga, Airsupra |
| Amgen INC. | $304.56 | 2025 | Repatha, Krystexxa, Otezla |
| Axsome Therapeutics, INC. | $304.25 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $262.51 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Phathom Pharmaceuticals, INC. | $214.99 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $179.33 | 2023-2025 | Epclusa, Vemlidy |
| Viiv Healthcare Company | $147.38 | 2025 | Dovato, Apretude |
| Novo Nordisk INC | $141.50 | 2025 | Wegovy |
| Dexcom, INC. | $133.27 | 2023 | Dexcom G7 Gss (161) |
| Inspire Medical Systems, INC. | $109.96 | 2024 | Inspire |
| Exact Sciences Corporation | $97.31 | 2025 | The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $92.81 | 2025 | Watchman Flx |
| Pfizer INC. | $76.50 | 2023-2024 | |
| Vanda Pharmaceuticals INC. | $54.16 | 2025 | Fanapt |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $39.79 | 2025 | Pifeltro, Capvaxive |
| Alkermes, INC. | $33.62 | 2025 | Lybalvi, Vivitrol |
| Lilly USA, LLC | $31.82 | 2024-2025 | Mounjaro, Zepbound |
| Shield Therapeutics INC | $27.84 | 2024 | |
| Astellas Pharma US INC | $24.20 | 2025 | Veozah |
| Lundbeck LLC | $17.98 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Debarbieris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.